stars 1 stars 2 stars 3

Founded in 2012, InnoSer is an innovative and dynamic contract research organization supporting preclinical development of drugs from its facilities in Belgium and the Netherlands. InnoSer supports its customers in the critical steps of their drug development journey with well characterized in vitro and in vivo disease models in addition to general drug development services, providing valuable insights into the mode of action, pharmacokinetics, safety, and efficacy of investigational compounds. Our services are designed with personalized tailoring in mind, supported by innovative technical capabilities and are executed in close collaboration with our partners. With a focus on nephrology, immuno-oncology, neurology and cardiometabolic disease, our current models include a growing selection of genetic and induced disease models. InnoSer enhances these offerings by providing state-of-the-art imaging and digital pathology options, along with facility management and support services including colony management. We embrace innovation to meet the needs of our partners and the evolving industry. With a focus on proactive problem solving, we have proven ourselves to be a flexible and professional partner in the market. Together we create a smart road to better health.

InnoSer Questions

The InnoSer annual revenue was $5 million in 2026.

Yanick Fanton is the Chief Scientific Officer of InnoSer.

31 people are employed at InnoSer.

The NAICS codes for InnoSer are [54, 541, 541714, 54171, 5417].

The SIC codes for InnoSer are [87, 873].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users